Australian Public Assessment Reports for prescription medicines (AusPARs)
An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.
Before a prescription medicine can be made available in Australia, the company legally responsible for supplying the product must lodge a submission with the TGA. The TGA then evaluates the safety, quality and effectiveness of the product to determine if the benefits to people taking the medicine outweigh the risks.
If a company wants to change something about the medicine once it is available, they also need to lodge a submission for the TGA to evaluate.
Please be aware that the AusPAR contains the version of the Product Information for that prescription medicine which was approved with the submission which the AusPAR describes. Product Information may have been updated since the AusPAR was prepared. For the current Product Information for a medicine please see: Product Information (PI).
AusPAR format, July 2013
The format of AusPARs was updated to give a clearer focus on the outcomes of the TGA's evaluation process and the rationale on which a decision to accept or reject an application is made.
An Extract from the full Clinical Evaluation Report is now included as an Attachment to the AusPAR. The Extract contains the information that was previously included in the body of the AusPAR itself, which now includes only the clinical evaluator's summaries of pharmacokinetics, pharmacodynamics, efficacy and safety, as well as the first and second round benefit-risk assessments.
This change has not altered the overall content of the AusPAR.
AusPAR paper co-authored with EMA in Drug Discovery Today, June 2016
Co-authoring with the European Medicines Agency (EMA), TGA published a peer-reviewed, open access review article on transparency in medicines regulation, including AusPARs and EPARs.
The article followed collaboration between two established medicines regulators who reflected on their experiences and future roles in communicating medicines information.
The paper can be freely viewed at: Transparency in drug regulation: public assessment reports in Europe and Australia Drug Discovery Today, online 29 June 2016.
More information about AusPARs
- AusPARs: Questions & answers
An AusPAR summarises the steps in the evaluation process that led the TGA to approve or not approve a prescription medicine submission
- Australian Public Assessment Report (AusPAR) guidance
Information about the structure, and processes for the compilation, review and publishing of an AusPAR
- AusPAR mailing list
Sign up to receive an email notification every time a new AusPAR is published
- AusPAR user survey
From 2 May 2016 to 31 July 2016, TGA ran a survey to receive feedback about the AusPARs for prescription medicines.
The findings helped TGA understand the audience of AusPARs, what AusPARs are used for, and the suitability of their content to external stakeholders.
TGA will soon publish the findings from this survey.
|Active ingredient||Product name|
|18 October 2016|
|13 October 2016|
|Sacubitril / Valsartan salt complex||Entresto / Novartis sacubitril/valsartan|
- Browse AusPARs by active ingredient
The active ingredient is the component in the medicine that makes it work
- Browse AusPARs by product name
The product name is the registered trademark or unique name of the medicine appearing on the label
- Browse AusPARs by sponsor
The sponsor is the person or company responsible for applying to the TGA to have their medicine included in the Australian Register of Therapeutic Goods